[ banner - AUA NEWS ]

FOR IMMEDIATE RELEASE: October 23, 2013

Contact:
Christine Frey, AUA
410-999-7091, Cfrey@auanet.org

AMERICAN UROLOGICAL ASSOCIATION TO LAUNCH THE FIRST NATIONAL LEVEL UROLOGY CLINICAL DATA REGISTRY

Linthicum, MD, October 23,2013 – As part of its ongoing commitment to improving the quality of care for patients with urologic disease, the AUA today announced it is developing the AUA Quality (AQUA) Registry. This is the first specialty-wide urologic registry at a national level, designed to measure and report healthcare quality and patient outcomes and provide data to help identify patterns and trends in the diagnosis and treatment of prostate cancer and eventual outcomes related to treatment options. The registry will be launched in 2014.

The AQUA Registry will initially focus on prostate cancer and will, for the first time, enable urologists to review their practice patterns and outcomes in comparison with their peers. It will gradually expand to include other urological conditions.

“The AUA AQUA Registry will be a powerful tool for urologists to observe the course of a disease, understand variations in treatment and outcomes, and examine factors influencing prognosis and quality of life,” explained Gopal Badlani, MD, AUA Secretary and Professor of Urology, Vice Chair for Clinical Affairs, and Director of the Urogynecology Regenerative Medicine Program at Wake Forest Baptist Medical Center in Winston-Salem, NC. “It can also help urologists describe patient care patterns, monitor safety and harm and enable them to review and compare data with their peers.”

Additionally, participating urologists will be kept informed of AUA clinical guidelines and will receive feedback regarding their individual- and/or practice-level performance on a range of process and outcome quality measures, benchmarked against the broader Registry data.These will help facilitate both the Centers for Medicare and Medicaid Services’ Physician Quality Reporting System (PQRS) and potentially regional and national certification requirements. Furthermore, AQUA’s clinical focus will be longitudinal follow-up of patients with prostate cancer and include a personalized portal for patients to report self-perceived outcomes on their quality of life.

“Both physicians and patients will benefit from the AQUA Registry inclusion of patient-reported outcomes that have, for the most part, been a void in registries to date,” said J. Quentin Clemens, MD, FACS, MSCI, Associate Professor of Urology at the University of Michigan and Chair of the AUA Data Committee.  “These outcomes are recognized as the most appropriate instruments to assess the effectiveness of healthcare interventions from the patient’s perspective,” he added.

The AUA AQUA Registry will be implemented in a phased manner over two years in terms of number of participating practices, scope and functionality.

“The AUA has been conducting its due diligence on the registry for nearly five years,” said AUA Executive Director Michael T. Sheppard, CPA, CAE. “This Registry will help patients and providers make shared decisions and government policy-makers understand patient safety, costs of care and system effectiveness.”

The registry is being developed under a sophisticated information technology infrastructure and through the aggregation and organization of both clinician- and patient-reported data on diagnostic and therapeutic interventions, clinical and quality of life outcomes and resource utilization, the AUA AQUA Registry will provide the urologic community with a definitive resource for informing and advancing urology within the United States. For more information, please visit http://www.auanet.org/resources/quality-registry.cfm

###